Repotrectinib

Contraindicated

Repotrectinib Lefamulin Xenleta Reduced lefamulin exposure, reduced efficacy of lefamulin, an increased repotrectinib exposure and an increased risk of repotrecti... Details

Major

Repotrectinib Clindamycin ANTIROBE Explained Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Colchicine Colcrys Explained Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Abemaciclib Verzenio Explained Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Abrocitinib Cibinqo Explained Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Acalabrutinib Calquence Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Atogepant Qulipta Reduced atogepant exposure Details Repotrectinib Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Repotrectinib Azithromycin AzaSite Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Atorvastatin Atorvaliq Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Repotrectinib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Repotrectinib Alogliptin Nesina Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Amlodipine Amvaz® Reduced amLODIPine exposure Details Repotrectinib Axitinib Inlyta Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Repotrectinib Bosutinib Bosulif Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Brigatinib Alunbrig Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Repotrectinib Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Repotrectinib Canagliflozin Invokana Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Capmatinib Tabrecta Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Captopril Capoten® Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Clindamycin Injection ANTIROBE Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Clindamycin Topical C/T/S® Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Clindamycin Vaginal Cleocin Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Cobimetinib Cotellic Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Cyclosporine Injection Atopica Increased repotrectinib exposure, an increased risk of repotrectinib-related adverse effects, reduced cycloSPORINE exposure and re... Details Repotrectinib Cyclosporine Ophthalmic Cequa Increased repotrectinib exposure, an increased risk of repotrectinib-related adverse effects, reduced cycloSPORINE exposure and re... Details Repotrectinib Dasatinib Phyrago Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Dihydroergotamine Nasal Spray Migranal Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Docetaxel Beizray Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Docetaxel Injection Beizray Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Dofetilide Tikosyn Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Repotrectinib Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details Repotrectinib Elacestrant Orserdu Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Enasidenib Idhifa Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Repotrectinib Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Repotrectinib Entrectinib Rozlytrek Increased repotrectinib exposure, an increased risk of repotrectinib-related adverse effects, reduced CYP3A4 substrates exposure a... Details